查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1733379

全球兒科疫苗開發市場規模（按類型、技術、應用、區域範圍和預測）

Global Pediatric Vaccines Development Market Size By Type (Monovalent, Multivalent), By Technology (Live Attenuated, Inactivated, Subunit), By Application (Infectious Disease, Cancer, Allergy), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

兒童疫苗開發市場規模及預測

2024 年兒科疫苗開發市場規模價值為 314 億美元，預計到 2032 年將達到 686 億美元，在 2026-2032 年預測期內的複合年成長率為 10.3%。

千禧世代中，科技主導的個人成長平台的日益普及也有望對預測期內的市場成長產生正面影響。預計預測期內，人們對疫苗和免疫意識的提高將推動全球兒科疫苗開發市場的成長。全球兒科疫苗開發市場報告對市場進行了全面的評估。它對關鍵細分市場、趨勢、市場促進因素、限制因素、競爭格局以及在市場中發揮關鍵作用的因素進行了全面的分析。

推動全球兒科疫苗開發市場的因素

兒科疫苗開發市場的市場驅動力受到多種因素的影響。這些包括：

增加知識並專注於預防性醫療保健：隨著父母和醫療保健提供者對免疫接種在預防兒童疾病方面的價值的認知不斷提高，對兒科疫苗的需求也隨之增加。

政府措施和免疫計畫：政府主導的免疫計畫和舉措正在擴大免疫接種的涵蓋範圍，尤其是在開發中國家。

新型佐劑、遞送系統和重組 DNA 技術的開發是疫苗研究領域的技術進步之一，這些進步正在加速兒科疫苗的開發並提高其有效性和安全性。

感染疾病增多：兒童感染疾病持續爆發，包括麻疹、流感、肺炎和腦膜炎，推動了兒童疫苗的需求。

增加疫苗研發資金：政府、非營利組織和製藥公司對兒童疫苗研發的投入不斷增加，正在刺激創新並有助於擴大市場。

提高疫苗接種覆蓋率：全球對兒科免疫接種的需求受到提高疫苗接種覆蓋率的措施的推動，例如補種疫苗接種計劃和常規免疫接種計劃。

新興感染疾病威脅：伊波拉和茲卡病毒等新興感染疾病的威脅日益增加，凸顯了繼續努力生產疫苗以應對不斷演變的公共衛生問題的重要性。

專注於根除和消除疾病：全球為消除或減少麻疹和脊髓灰質炎等可透過疫苗預防的疾病所做的努力推動了兒童免疫接種的需求，這推動了市場的成長。

國際衛生組織、小兒科和其他醫療保健專業人員的倡導工作支持將疫苗接種作為公共衛生干預措施。這導致兒童疫苗的接受度和接種率有所提高。

技術和製造進步：基於細胞培養和重組疫苗製造平台以及其他疫苗製造技術的開發，使疫苗更具可擴展性、效率和成本效益，有助於擴大市場。

限制全球兒科疫苗開發市場的因素

多種因素可能對兒科疫苗開發市場造成市場限制和挑戰。這些包括：

嚴格的監管要求：兒科疫苗漫長的核准流程往往會延遲新產品的開發和上市。

開發成本高：由於開發兒科疫苗的成本高昂，包括研究和臨床測試，規模較小的生物技術公司和學術機構可能難以在市場上創新和競爭。

罕見疾病的市場潛力有限：開發針對罕見兒童疾病的疫苗成本很高，並且沒有可觀的投資收益來涵蓋開發成本。

錯誤訊息和疫苗不信任：錯誤訊息和疫苗不信任會阻礙疫苗宣傳活動，減少對兒童疫苗接種者的需求並阻礙市場擴張。

低溫運輸需求：維護疫苗分發和儲存的低溫運輸在物流上具有挑戰性且成本高昂，尤其是在農村和資源貧乏的地區。這可能會影響疫苗接種的取得和接種。

智慧財產權和專利問題：對疫苗接種技術和發展的擔憂可能導致法律糾紛和市場進入延遲，從而抑制創新和競爭。

疫苗供應鏈中斷，包括製造問題、原料短缺和分銷困難，可能會影響市場穩定並導致供不應求。

全球健康公平挑戰：高所得和低收入國家在獲得兒童疫苗方面存在的不平等可能會限制市場擴張並阻礙全民免疫的努力，從而加劇全球健康差距。

安全問題和不利事件：有關兒童免疫接種的安全問題和不利事件的報告可能會破壞公眾對免疫接種計劃的信任和信心。這可能會導致疫苗接種率和市場需求下降。

現有疫苗的競爭：在擁擠的疫苗市場中，來自安全性和有效性已得到證實的兒科疫苗的競爭會使新疫苗難以獲得市場佔有率。

目錄

第1章全球兒科疫苗開發市場介紹

  • 市場概覽
  • 研究範圍
  • 先決條件

第2章執行摘要

第3章：已驗證的市場研究調查方法

  • 資料探勘
  • 驗證
  • 第一手資料
  • 資料來源列表

第4章全球兒科疫苗發展市場展望

  • 概述
  • 市場動態
    • 驅動程式
    • 限制因素
    • 機會
  • 波特五力模型
  • 價值鏈分析

第5章 全球兒科疫苗開發市場（按類型）

  • 概述
  • 單一值
  • 多效價

第6章 全球兒童疫苗開發市場（依技術）

  • 概述
  • 生的
  • 失活
  • 次單元
  • 類毒素
  • 結合物
  • 其他

第7章 全球兒童疫苗開發市場（按應用）

  • 概述
  • 感染疾病
  • 癌症
  • 過敏

第8章 全球兒科疫苗開發市場（按地區）

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 其他
    • 拉丁美洲
    • 中東和非洲

第9章 全球兒科疫苗開發市場的競爭格局

  • 概述
  • 各公司市場排名
  • 重點發展策略

第10章 公司簡介

  • GlaxoSmithKline plc
  • Merck Sharp & Dohme Corp.
  • SANOFI
  • AstraZeneca
  • Pfizer, Inc.
  • Zydus Cadila
  • Indian Immunologicals Limited
  • Serum Institute of India Pvt. Ltd.
  • Mitsubishi Tanabe Pharma Corporation
  • Panacea BIoTec

第11章 附錄

  • 相關調查
簡介目錄
Product Code: 65663

Pediatric Vaccines Development Market Size And Forecast

Pediatric Vaccines Development Market size was valued at USD 31.4 Billion in 2024 and is projected to reach USD 68.6 Billion by 2032, growing at a CAGR of 10.3% from 2026 to 2032.

The rising popularity of technology-driven platforms for self-growth amongst millennials is also expected to positively impact market growth during the forecast period. Increasing awareness regarding vaccines and immunization among the populace is expected to boost the growth of the global Pediatric Vaccines Development Market over the forecast period. The Global Pediatric Vaccines Development Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Pediatric Vaccines Development Market Drivers

The market drivers for the Pediatric Vaccines Development Market can be influenced by various factors. These may include:

Growing Knowledge and Focus on Preventive Healthcare: The need for paediatric vaccines is being driven by parents' and healthcare professionals' growing understanding of the value of immunisation in preventing childhood illnesses.

Government Initiatives and Immunisation Programmes: Growing access to vaccinations, especially in developing nations, is being facilitated by government-led immunisation programmes and initiatives.

The development of new adjuvants, delivery systems, and recombinant DNA techniques is among the technological advancements in vaccine research that are speeding up the development of paediatric vaccines and enhancing their efficacy and safety profiles.

Growing Incidence of Infectious Diseases: The demand for paediatric vaccination is being driven by the persistent incidence of infectious diseases in children, including measles, influenza, pneumonia, and meningitis.

More Funding for Vaccine Research and Development: Growing investments in paediatric vaccine research and development from governments, nonprofits, and pharmaceutical corporations are stimulating innovation and propelling market expansion.

Increasing Vaccination Coverage: Worldwide demand for paediatric vaccinations is being driven by initiatives to raise vaccination coverage rates, such as catch-up vaccination programmes and regular immunisation schedules.

Threats from Emerging Infectious Diseases: The rise in threats from emerging infectious diseases, such the Ebola and Zika viruses, emphasises the significance of ongoing attempts to produce vaccines to address changing public health issues.

Emphasis on Disease Eradication and Elimination: Demand for paediatric vaccinations is being driven by global measures to eradicate or reduce vaccine-preventable illnesses like measles and polio, which is bolstering the growth of the market.

The promotion of vaccination as a public health intervention is being aided by the advocacy efforts of international health organisations, paediatricians, and other healthcare professionals. This has led to a rise in the acceptance and uptake of paediatric vaccines.

Technological and Manufacturing Advancements: The development of cell culture-based and recombinant vaccine production platforms, among other vaccine manufacturing technologies, is increasing the scalability, efficiency, and cost-effectiveness of vaccines and propelling their market expansion.

Global Pediatric Vaccines Development Market Restraints

Several factors can act as restraints or challenges for the Pediatric Vaccines Development Market. These may include:

Strict Regulatory Requirements: The lengthy and strict regulatory approval procedures for paediatric vaccines frequently cause delays in the development of new products and the launch of new products.

High Development expenses: Smaller biotechnology businesses and academic institutions may find it difficult to innovate and remain competitive in the market due to the high expenses involved in developing paediatric vaccines, which include research and clinical trials.

Limited Market Potential for Rare disorders: It can be expensive to create vaccines for rare paediatric disorders when there may not be a significant return on investment to cover development expenses.

Misinformation and Vaccine reluctance: Misinformation and vaccine mistrust can cause vaccine reluctance, which can obstruct immunisation campaigns, lower demand for paediatric vaccinations, and hamper market expansion.

Cold Chain requirements: It can be logistically difficult and expensive to maintain the cold chain for vaccine distribution and storage, particularly in rural and resource-constrained places. This can have an influence on vaccination accessibility and adoption.

Intellectual property rights and patent issues: Concerns over vaccination technology and development can give rise to legal battles and market entry delays, which can impede innovation and competition.

Disruptions in the vaccine supply chain, such as problems with manufacturing, shortages of raw materials, or difficulties with distribution, can affect the stability of the market and result in supply shortages.

Global Health Equity Challenges: Inequalities in high- and low-income nations' access to paediatric vaccines might worsen global health disparities by restricting market expansion and impeding attempts to attain universal immunisation coverage.

Safety worries and Adverse Events: The public's trust and confidence in vaccination programmes can be damaged by safety worries and reports of adverse events linked to paediatric vaccinations. This can result in a decline in vaccine uptake and market demand.

Competition from Established Vaccines: In crowded vaccine markets, it can be difficult for novel vaccines to obtain market share due to competition with established paediatric vaccines with well-known safety and effectiveness characteristics.

Global Pediatric Vaccines Development Market Segmentation Analysis

The Global Pediatric Vaccines Development Market is Segmented Based on Type, Technology, Application, And Geography.

Pediatric Vaccines Development Market, By Type

  • Monovalent
  • Multivalent

Based on Type, The market is bifurcated into Monovalent, Multivalent. The Monovalent segment is expected to inflate the market growth owing to their safety and stability and their ability to develop a rapid immune response.

Pediatric Vaccines Development Market, By Technology

  • Live Attenuated
  • Inactivated
  • Subunit
  • Toxoid
  • Conjugate
  • Others

Based on Technology, The market is bifurcated into Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate, Others. The Conjugate segment is expected to inflate the market growth. This can be attributed to an increase in the prevalence of pneumococcal and meningococcal infections and a rise in awareness regarding the prevention of diseases.

Pediatric Vaccines Development Market, By Application

  • Infectious Disease
  • Cancer
  • Allergy

Based on Application, The market is bifurcated into Infectious Disease, Cancer, and Allergy. Infectious Disease is anticipated to become the fastest-growing market in the forecast duration due to growing global awareness about immunization against a number of infectious diseases that cause mortality and morbidity.

Pediatric Vaccines Development Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the world
  • On the basis of Geography, The Global Pediatric Vaccines Development Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America is expected to hold the largest market share in the forecast period. Some of the key factors that can be attributed to its dominance are an increase in R&D investments by numerous companies and a rise in government support for immunization and the development of pediatric vaccines. In addition, the presence of advanced healthcare infrastructure and facilities for immunization supports the growth of this segment.

Key Players

The "Global Pediatric Vaccines Development Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are GlaxoSmithKline plc, Merck Sharp & Dohme Corp., SANOFI, AstraZeneca, Pfizer, Inc., Zydus Cadila, Indian Immunologicals Limited, Serum Institute of India Pvt. Ltd., Mitsubishi Tanabe Pharma Corporation, and Panacea Biotec. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL PEDIATRIC VACCINES DEVELOPMENT MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL PEDIATRIC VACCINES DEVELOPMENT MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL PEDIATRIC VACCINES DEVELOPMENT MARKET, BY TYPE

  • 5.1 Overview
  • 5.2 Monovalent
  • 5.3 Multivalent

6 GLOBAL PEDIATRIC VACCINES DEVELOPMENT MARKET, BY TECHNOLOGY

  • 6.1 Overview
  • 6.2 Live Attenuated
  • 6.3 Inactivated
  • 6.4 Subunit
  • 6.5 Toxoid
  • 6.6 Conjugate
  • 6.7 Others

7 GLOBAL PEDIATRIC VACCINES DEVELOPMENT MARKET, BY APPLICATION

  • 7.1 Overview
  • 7.2 Infectious Disease
  • 7.3 Cancer
  • 7.4 Allergy

8 GLOBAL PEDIATRIC VACCINES DEVELOPMENT MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East & Africa

9 GLOBAL PEDIATRIC VACCINES DEVELOPMENT MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 GlaxoSmithKline plc
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 Merck Sharp & Dohme Corp.
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 SANOFI
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 AstraZeneca
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 Pfizer, Inc.
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Zydus Cadila
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 Indian Immunologicals Limited
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 Serum Institute of India Pvt. Ltd.
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments
  • 10.9 Mitsubishi Tanabe Pharma Corporation
    • 10.9.1 Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Outlook
    • 10.9.4 Key Developments
  • 10.10 Panacea Biotec
    • 10.10.1 Overview
    • 10.10.2 Financial Performance
    • 10.10.3 Product Outlook
    • 10.10.4 Key Developments

11 Appendix

  • 11.1 Related Research